A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

Trial Profile

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs MGD 013 (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors MacroGenics
  • Most Recent Events

    • 05 Sep 2017 According to a MacroGenics media release, the first patient has been dosed in this trial.
    • 15 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 02 Aug 2017 According to a MacroGenics media release, an Investigational New Drug Application (IND) for MGD013 was cleared by FDA and the company expects to dose the first patients in the coming weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top